drugset
drugset / Trial / NCT04656795

PK Study in Subjects With Renal Impairment (Severe and if Required Mild & Moderate) Compared to Subjects With Normal Renal Function

NCT04656795 ↗

Phase 1 Completed 32 enrolled Tanabe Pharma America, Inc.
Non-randomizedParallel-groupOpen-labelOther

Summary

This is an open-label, non randomised, single-dose, study in male and female subjects with renal impairment (severe and if required mild \& moderate) compared to male and female subjects with normal renal function.

Timeline

Start
2020-12-02
Primary completion
2021-12-04
Completion
2021-12-09

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Dersimelagon Small molecule 300 mg —

Indications

impaired renal function disease